Trinity Biotech to Begin European Pre-Pivotal Trial to Optimize its CGM Sensor

Core Insights - Trinity Biotech is advancing its next generation continuous glucose monitoring (CGM) solution towards market launch, having received regulatory approval for an initial European pre-pivotal trial [5][6] - The pre-pivotal trial is expected to begin imminently and be completed by the end of July, with data from this trial to inform a larger pivotal trial planned for 2025 [1][5] Company Overview - Trinity Biotech is a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors [6] - The company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments, and has recently entered the wearable biosensor industry [6] Technology and Innovation - The company has been working on innovations and improvements to its CGM technology since acquiring it earlier in the year [5] - The CGM solution and AI-driven health and wellness analytics technology are viewed as key long-term growth drivers for the company [5]